Literature DB >> 32194702

Downregulation of extracellular vesicle microRNA-101 derived from bone marrow mesenchymal stromal cells in myelodysplastic syndrome with disease progression.

Yuu Saitoh1,2, Tomohiro Umezu1,3, Satoshi Imanishi4, Michiyo Asano1, Seiichiro Yoshizawa1, Seiichiro Katagiri1, Tamiko Suguro1, Hiroaki Fujimoto1, Daigo Akahane1, Chiaki Kobayashi-Kawana1, Junko H Ohyashiki4,5, Kazuma Ohyashiki1,5.   

Abstract

To evaluate the mechanism underlying the communication between myeloid malignant and bone marrow (BM) microenvironment cells in disease progression, the current study established BM mesenchymal stromal cells (MSCs) and assessed extracellular vesicle (EV) microRNA (miR) expression in 22 patients with myelodysplastic syndrome (MDS) and 7 patients with acute myeloid leukemia and myelodysplasia-related changes (AML/MRC). Patients with MDS were separated into two categories based on the revised International Prognostic Scoring System (IPSS-R), and EV-miR expression in BM-MSCs was evaluated using a TaqMan low-density array. The selected miRs were evaluated using reverse transcription-quantitative PCR. The current study demonstrated that the expression of BM-MSC-derived EV-miR was heterogenous and based on MDS severity, the expression of EV-miR-101 was lower in high-risk group and patients with AML/MRC compared with the control and low-risk groups. This reversibly correlated with BM blast percentage, with which the cellular miR-101 from BM-MSCs or serum EV-miR-101 expression exhibited no association. Database analyses indicated that miR-101 negatively regulated cell proliferation and epigenetic gene expression. The downregulation of BM-MSC-derived EV-miR-101 may be associated with cell-to-cell communication and may accelerate the malignant process in MDS cells.
Copyright © 2020, Spandidos Publications.

Entities:  

Keywords:  bone marrow mesenchymal stroma cells; disease progression; extracellular vesicle; microRNA-101; myelodysplastic syndrome

Year:  2020        PMID: 32194702      PMCID: PMC7038917          DOI: 10.3892/ol.2020.11282

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  37 in total

Review 1.  Immunomodulatory properties of mesenchymal stromal cells.

Authors:  Alma J Nauta; Willem E Fibbe
Journal:  Blood       Date:  2007-07-30       Impact factor: 22.113

Review 2.  Mesenchymal stromal cells: sensors and switchers of inflammation.

Authors:  Maria Ester Bernardo; Willem E Fibbe
Journal:  Cell Stem Cell       Date:  2013-10-03       Impact factor: 24.633

3.  Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Peter L Greenberg; Richard M Stone; Aref Al-Kali; Stefan K Barta; Rafael Bejar; John M Bennett; Hetty Carraway; Carlos M De Castro; H Joachim Deeg; Amy E DeZern; Amir T Fathi; Olga Frankfurt; Karin Gaensler; Guillermo Garcia-Manero; Elizabeth A Griffiths; David Head; Ruth Horsfall; Robert A Johnson; Mark Juckett; Virginia M Klimek; Rami Komrokji; Lisa A Kujawski; Lori J Maness; Margaret R O'Donnell; Daniel A Pollyea; Paul J Shami; Brady L Stein; Alison R Walker; Peter Westervelt; Amer Zeidan; Dorothy A Shead; Courtney Smith
Journal:  J Natl Compr Canc Netw       Date:  2017-01       Impact factor: 11.908

4.  MicroRNA-101 inhibits the migration and invasion of intrahepatic cholangiocarcinoma cells via direct suppression of vascular endothelial growth factor-C.

Authors:  Gang Deng; Yinglu Teng; Feizhou Huang; Wanpin Nie; Lei Zhu; Wei Huang; Hongbo Xu
Journal:  Mol Med Rep       Date:  2015-08-21       Impact factor: 2.952

5.  Methyl jasmonate induces the apoptosis of human colorectal cancer cells via downregulation of EZH2 expression by microRNA‑101.

Authors:  Zheng Peng; Yong Zhang
Journal:  Mol Med Rep       Date:  2016-12-20       Impact factor: 2.952

6.  Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts.

Authors:  Jerome Paggetti; Franziska Haderk; Martina Seiffert; Bassam Janji; Ute Distler; Wim Ammerlaan; Yeoun Jin Kim; Julien Adam; Peter Lichter; Eric Solary; Guy Berchem; Etienne Moussay
Journal:  Blood       Date:  2015-06-22       Impact factor: 22.113

7.  Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1.

Authors:  Tomohiro Umezu; Hiroko Tadokoro; Kenko Azuma; Seiichiro Yoshizawa; Kazuma Ohyashiki; Junko H Ohyashiki
Journal:  Blood       Date:  2014-10-15       Impact factor: 22.113

8.  MicroRNA-101 induces apoptosis in cisplatin-resistant gastric cancer cells by targeting VEGF-C.

Authors:  Guangyan Li; Fang Yang; Shiyu Gu; Zhenjuan Li; Minghui Xue
Journal:  Mol Med Rep       Date:  2015-11-12       Impact factor: 2.952

9.  DICER1 gene and miRNA dysregulation in mesenchymal stem cells of patients with myelodysplastic syndrome and acute myeloblastic leukemia.

Authors:  Hakan Ozdogan; Bala Gur Dedeoglu; Yasemin Oztemur Islakoglu; Alp Aydos; Sevil Kose; Arzu Atalay; Zeynep Arzu Yegin; Ferit Avcu; Duygu Uckan Cetinkaya; Osman Ilhan
Journal:  Leuk Res       Date:  2017-10-31       Impact factor: 3.156

10.  Genetic variations of bone marrow mesenchymal stromal cells derived from acute leukemia and myelodysplastic syndrome by targeted deep sequencing.

Authors:  Kenko Azuma; Tomohiro Umezu; Satoshi Imanishi; Michiyo Asano; Seiichiro Yoshizawa; Seiichiro Katagiri; Kazuma Ohyashiki; Junko H Ohyashiki
Journal:  Leuk Res       Date:  2017-09-21       Impact factor: 3.156

View more
  1 in total

Review 1.  Extracellular Vesicles in Myeloid Neoplasms.

Authors:  Christina Karantanou; Valentina René Minciacchi; Theodoros Karantanos
Journal:  Int J Mol Sci       Date:  2022-08-08       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.